BMO Capital raised its price target on Rigel Pharmaceuticals (NASDAQ: RIGL) to $10.00 (from $8.00) while maintaining a Outperform rating.Analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Rigel Pharmaceuticals (RIGL) PT Raised to $9 at Cantor FitzgeraldMay 2, 2018 2:27 AM Rigel Pharmaceuticals (RIGL) PT Raised to $8 at Piper JaffrayMay 2, 2018 2:20 AM Rigel Pharma (RIGL) Tops Q1 EPS by 1cMay 1, 2018 4:08 PM